$RCUS SEC Filings

Arcus Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwrite...

Based upon preliminary estimates and information available to Arcus Biosciences, Inc. (the “Company”) as of October 21, 2026, the Company estimates that it had approximately $694.0 million in cash, cash equivalents and marketable securit...

On October 20, 2026, Arcus Biosciences, Inc. presented new data from the ARC-20 platform study evaluating casdatifan, alone or in combination, as a first-, second- and late-line treatment for clear cell renal cell carcinoma (“ccRCC”). Th...

Received 2,827 shares by exercise or conversion ($43.6K) · Sold 2,827 shares ($84.8K)

Sold 48,502 shares ($1.46M) · Sold 20,067 shares ($574K)

Sold 9,236 shares ($250K) · Sold 15,764 shares ($437K) · Sold 6,431 shares ($191K)

Received 5,700 shares as a grant or award · Granted 16,900 Stock Option (Right to Buy)

Received 5,700 shares as a grant or award · Granted 16,900 Stock Option (Right to Buy)

Received 5,700 shares as a grant or award · Granted 16,900 Stock Option (Right to Buy)

Received 34,090 shares by exercise or conversion ($87.7K)